Cumberland Pharmaceuticals INC

Cumberland Pharmaceuticals announced the closing of its strategic transaction with Apotex Health for $100 million, alongside a special dividend and updated clinical trial results.

Cumberland Pharmaceuticals Inc. announced a special cash dividend of $1.50 per share following a strategic transaction with Apotex, alongside a new $5 million share repurchase program.

Cumberland Pharmaceuticals Inc. announced the closing of its strategic transaction with an affiliate of Apotex Inc., selling its branded U.S. product lines for $100 million to focus on rare disease pipeline development.

Cumberland Pharmaceuticals shareholders have voted to approve the strategic asset sale of its commercial products to an affiliate of Apotex Inc.

Cumberland Pharmaceuticals reports Q1 2026 financial results and a $100 million strategic divestiture of its branded portfolio.

Cumberland Pharmaceuticals shareholders approved the election of directors and ratified the appointment of its independent auditor at the 2026 annual meeting.

Cumberland Pharmaceuticals Inc. has completed a strategic transaction with Apotex, divesting its FDA-approved brands for $100 million to sharpen its focus on developing innovative product candidates.

Cumberland Pharmaceuticals announced a definitive agreement to sell its portfolio of FDA-approved commercial brands to Apotex for $100 million in cash.

Cumberland Pharmaceuticals reported a significantly reduced net loss for the nine months ended September 30, 2025, driven by increased product sales and strategic co-commercialization agreements, despite a quarterly revenue dip.

Cumberland Pharmaceuticals Inc. reported a significant turnaround, achieving net income in the first half of 2025 driven by robust revenue growth from key products and a milestone payment, alongside promising clinical trial advancements.

Cumberland Pharmaceuticals reports a profitable first quarter of 2025, driven by a milestone payment for Vibativ approval in China and increased revenues from Kristalose and Sancuso.

Cumberland Pharmaceuticals reported a net revenue decrease in the third quarter of 2024 compared to the same period last year, alongside updates on clinical trials and product developments.

Cumberland Pharmaceuticals' 2024 10-K filing reveals a slight revenue decrease, strategic shifts in product focus, and continued investment in its clinical pipeline, particularly ifetroban.

Cumberland Pharmaceuticals' 10-K filing outlines its common stock characteristics, anti-takeover provisions, and business operations, including product portfolio and clinical pipeline.

Cumberland Pharmaceuticals Director Martin S. Brown Jr. acquired 1,800 shares of common stock at $2.80 per share.

Cumberland Pharmaceuticals Director Joseph C. Galante acquired 1,800 shares of common stock, increasing his beneficial ownership.

Cumberland Pharmaceuticals Director James Jones acquired 1,800 shares of common stock, increasing his beneficial ownership.

Cumberland Pharmaceuticals Director Kenneth Krogulski acquired 5,800 shares of common stock at $2.80 per share, increasing his direct beneficial ownership to 302,338 shares.

Cumberland Pharmaceuticals Director Caroline Young reported a planned acquisition of 1,800 shares of common stock at $2.80 per share.

Cumberland Pharmaceuticals' Vice President of Organizational Development, Todd M. Anthony, acquired 3,000 stock options at an exercise price of $2.80.

Cumberland Pharmaceuticals Inc. will hold its annual shareholder meeting on April 22, 2025, to vote on the election of directors and the ratification of its independent accounting firm.

Cumberland Pharmaceuticals will hold its Annual Meeting of Shareholders on April 22, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Cumberland Pharmaceuticals Inc. will hold its annual shareholder meeting on April 23, 2024, to vote on director elections and ratify the appointment of its independent accounting firm.

Cumberland Pharmaceuticals will hold its annual shareholder meeting on April 23, 2024, to vote on director elections and the ratification of its independent accounting firm.

Cumberland Pharmaceuticals Inc. CEO A.J. Kazimi has reported beneficial ownership of 38.07% of the company's common stock.

Millennium Management and affiliated entities reported a 4.0% passive beneficial ownership stake in Cumberland Pharmaceuticals Inc. as of September 30, 2025.

Ikarian Capital, LLC and Neil Shahrestani have jointly filed a Schedule 13G, reporting a passive beneficial ownership of 4.9% of Cumberland Pharmaceuticals Inc.'s common stock.

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a beneficial ownership of 5.8% in Cumberland Pharmaceuticals Inc.

A.J. Kazimi, CEO of Cumberland Pharmaceuticals Inc., has disclosed beneficial ownership of 40.8% of the company's common stock.

Millennium Management LLC, along with its affiliates Integrated Core Strategies (US) LLC, Millennium Group Management LLC, and Israel A. Englander, have disclosed a passive beneficial ownership of 8.8% in Cumberland Pharmaceuticals Inc.